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Background: It is now recognized that TSH can act on targets other than the thyroid, including the liver. Elevated
serum TSH levels in euthyroid subjects were recently reported to correlate with high values of serum proprotein
convertase subtilisin/kexin type 9 (PCSK9). This protein, expressed and secreted by hepatocytes, promotes higher
LDL-cholesterol levels. We tested whether an acute increase of TSH levels following administration of TSH in vivo
would raise PCSK9 levels in patients who had previously undergone total thyroidectomy and radioablation for
thyroid cancer.
Findings: TSH levels rose from 0.64 ± 1.02 mU/L on day 1 to 98.66 ± 4.83 mU/L on day 3, following injections of
recombinant human TSH (on days 1 and 2). PCSK9 levels were 330 ± 99 ng/ml on day 1, and did not change on
days 3 or 5 in response to TSH stimulation.
Conclusions: Although a positive correlation between TSH and PCSK9 in euthyroid subjects has raised the possibility
that TSH might act on the liver to raise PCSK9 values, our data show that PCSK9 levels are not affected by acute
elevations of TSH levels. Whether chronic elevations of TSH are needed to upregulate PCSK9 remains to be determined.
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Introduction
The TSH receptor is classically expressed in thyrocytes.
In response to TSH, it activates downstream intracellular
signaling events to stimulate thyroid hormone produc-
tion and cell proliferation [1]. It is now appreciated that
TSH receptors are also expressed in non-thyroidal tis-
sues [2]. The physiological significance of this extra-
thyroidal expression has not yet been clarified, but regu-
lation of bone development, adipose tissue remodelling,
and hepatocyte cholesterol metabolism have been pro-
posed [3-5].
Acute non-thyroidal effects of TSH, in the setting of
normal thyroid hormone levels, can be studied in vivo
with recombinant human (rh)TSH stimulation. It is used
for thyroid cancer screening in patients who have under-
gone total thyroidectomy followed by radioablation of* Correspondence: asorisky@ohri.ca
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unless otherwise stated.any remnant tissue. For example, rhTSH stimulation has
been shown to increase circulating IL-6, CRP, oxidative
stress markers, and non-esterified fatty acids, and to de-
crease endothelial relaxation in these patients who have
no thyroid glands [6-8].
Levels of TSH, but not free T4 (FT4), correlate posi-
tively with proprotein convertase subtilisin/kexin type 9
(PCSK9) in euthyroid, non-obese subjects [9]. PCSK9,
expressed in hepatocytes, is secreted and binds to the
LDL receptor. It directs the receptor to lysosomal deg-
radation rather than a recycling pathway, lowering the
number of LDL receptors expressed on the cell surface,
and thereby leading to an increase in LDL cholesterol
[10] . Hepatocytes are an extra-thyroidal target of TSH,
which regulates the expression of 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase, and therefore, choles-
terol metabolism [5]. Therefore, it was suggested that
TSH might possibly act on hepatocytes to raise PCSK9
levels [9].
Our objective was to determine if PCSK9 levels would
rise in patients previously treated for thyroid cancer
undergoing acute rhTSH stimulation.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Gagnon et al. Thyroid Research 2014, 7:4 Page 2 of 3
http://www.thyroidresearchjournal.com/content/7/1/4Patients and methods
Patients
14 patients (10 women) were recruited (Ottawa Hospital
Research Ethics Board #2006558). All had undergone
total thyroidectomy and radioablative iodine therapy for
thyroid cancer, and were on L-thyroxine treatment. They
were healthy without evidence of metastatic disease.
Each received 0.9 mg rhTSH on days 1 and 2, and blood
samples were drawn on days 1 (prior to rhTSH), 3, and 5.
Figure 1A shows the baseline characteristics.
Assays
PCSK9 was measured using the PCSK9 Quantikine
ELISA kit (#DPC900; R&D Systems). TSH and free thy-
roxine were measured in The Ottawa Hospital clinical
biochemistry laboratory by AutoIA (Abbot Dxl).
Statistical analysis
Data were assessed by analysis of variance, and by posthoc
Newman-Keul tests for multiple comparisons, or by un-
paired t-test, with P < 0.05 taken as significant. Values of
TSH reported by the clinical laboratory as “>100 mU/L”
were taken as “100 mU/L” for calculation of mean ± SD.
Pearson’s regression and correlation analysis were per-
formed using Graph-Pad Instat version 3.
Results
Basal studies
Overall basal parameters are shown in Figure 1A. At


























Figure 1 Acute rhTSH administration does not alter serum PCSK9 lev
laboratory range values (A). Serum TSH (B) and PCSK9 (C) levels at baseline
mean ± SD of 14 patient samples.participants was 330 ± 99 ng/ml. In the females (n = 10),
baseline value was 351 ± 90 ng/ml, and in the males
(n = 4), it was 276 ± 113 ng/ml. The difference be-
tween PCSK9 values in females versus males was not
significant.
There was a trend towards a correlation between base-
line PCSK9 values in all participants and BMI (r = 0.47;
p =0.09). Further analysis showed this was a result of a
significant positive correlation with BMI in the females
(r = 0.783, p = 0.0073).
In patients with BMI < 30 (n = 10), PCSK9 (mean ± SD)
was 317 ± 83 ng/ml versus 360 ± 141 ng/ml in patients
with BMI > 30 (n = 4) (not significant).
There was no correlation between baseline PCSK9 and
age, TSH, or FT4 value.
Stimulated studies
Administration of rhTSH increased TSH levels (mean ± SD)
from 0.64 ± 1.02 mU/L on day 1, to 98.66 ± 4.83 mU/L
on day 3, and to 16.43 ± 7.76 mU/L on day 5 (Figure 1B).
There was no change in PCSK9 values from the base-
line value (Figure 1C). PCSK9 (mean ± SD) was 334 ±
139 ng/ml on day 3, and 305 ± 111 ng/ml on day 5. The
same lack of response was also observed when partici-
pants were divided according to gender or obesity status
(BMI <30 versus > 30).
Conclusions
PCSK9, an important regulator of lipoprotein metabol-





















.9 ± 3.6 7.0-17.0
4 ± 1.02 0.30-5.60
els. Baseline characteristics of the patient population and normal
(day 1), on day 3 and day 5 after rhTSH injection. Results are the
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Hepatocytes, the major source of PCSK9, are TSH-
responsive cells with respect to 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase expression and cholesterol
metabolism [5]. On that basis, it was proposed that TSH
might act on hepatocytes to stimulate PCSK9 release [9].
This prompted us to determine whether acute rhTSH ad-
ministration would raise PCSK9 levels.
Our results indicate there is no change of serum levels
of PCSK9 in response to acute rhTSH stimulation in
non-obese or obese patients, despite the high levels of
TSH achieved. Our baseline PCSK9 data, pointing to a
positive correlation with BMI, are in agreement with
other studies [10] .
Our observations are not consistent with the recently
reported correlation of PCSK9 and TSH in 64 non-
obese euthyroid subjects [9]. There was no such correl-
ation of PCSK9 with FT4, so that effects on PCSK9 were
thought to be due to direct effects of TSH on the hep-
atocyte independent of hypothyroidism.
However, several limitations of our study should be
considered. Our study sample is relatively small, and
may have been under-powered to detect a small response
of PCSK9 to rhTSH. The stimulation protocol with rhTSH
in our patients is acute, and perhaps a chronic elevation of
TSH over weeks to months is required to alter hepatocyte
PCSK9 production and secretion to elevate serum values.
We were also limited to sampling blood on day 3 and day
5, according to the clinical protocol, so we cannot rule out
either a very early response to rhTSH, eg on day 2, or a de-
layed response after day5. We also note that thyroxine
therapy in our patients is aimed at keeping FT4 values to-
ward the high end of normal, in order to target endogen-
ous TSH levels to the low end of normal, and it is possible
that might attenuate responsiveness to exogenous rhTSH
administration.
Further studies in patients with subclinical hypo-
thyroidism, characterized by chronically elevated TSH
but normal thyroxine levels, may clarify whether TSH is
positively correlated with PCSK9. It may also be inform-
ative to treat human hepatocytes in culture with TSH to
determine if it can directly increase PCSK9 expression
and/or secretion.
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